Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Solid Biosciences Inc. (SLDB : NSDQ)
 
 • Company Description   
Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts.

Number of Employees: 100

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.03 Daily Weekly Monthly
20 Day Moving Average: 1,773,086 shares
Shares Outstanding: 77.51 (millions)
Market Capitalization: $389.90 (millions)
Beta: 2.34
52 Week High: $10.37
52 Week Low: $2.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 18.35% 11.94%
12 Week 88.39% 58.05%
Year To Date 25.75% 17.78%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 RUTHERFORD AVENUE THIRD FLOOR
-
CHARLESTOWN,MA 02129
USA
ph: 617-337-4680
fax: -
lmonteiro@solidbio.com http://www.solidbio.com
 
 • General Corporate Information   
Officers
Alexander Cumbo - Chief Executive Officer; President and Director
Ian F. Smith - Chairman of the Board
David Tyronne Howton - Chief Operating Officer and Secretary
Kevin Tan - Chief Financial Officer and Treasurer
Martin Freed - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 83422E204
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 77.51
Most Recent Split Date: 10.00 (0.07:1)
Beta: 2.34
Market Capitalization: $389.90 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.32
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 7.81%
vs. Previous Quarter: 33.71%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -68.15
12/31/24 - -67.74
ROA
06/30/25 - -
03/31/25 - -55.33
12/31/24 - -54.51
Current Ratio
06/30/25 - -
03/31/25 - 10.89
12/31/24 - 5.20
Quick Ratio
06/30/25 - -
03/31/25 - 10.89
12/31/24 - 5.20
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 3.80
12/31/24 - 3.43
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©